This clinical trial aims to evaluate the efficacy, safety of FOLFIRI with vemurafenib and cetuximab in Advanced Colorectal Cancer Patients with BRAF V600E mutation.
Name: Vemurafenib
Name: Cetuximab
Description: Evaluation of tumor burden based on RECIST criteria every 4 cycles(each cycle is 14 days), ORR is the proportion of patients with reduction in tumor burden of a predefined amount, including complete response and partial response.
Measure: Objective Respone Rate(ORR) Time: up to 55monthsDescription: (ETS) rate is defined as 20% reduction in target lesions after the first 6 weeks of treatment (first tumor assessment)
Measure: Early tumor shrinkage (ETS) rate Time: up to 55monthsDescription: Evaluation of tumor burden based on RECIST criteria every 4 cycles(each cycle is 14 days), and DCR is the proportion of patients with reduction in tumor burden of a predefined amount, including complete response, partial response and stable disease
Measure: Disease Control Rate (DCR) Time: up to 55monthsAllocation: N/A
Single Group Assignment
There is one SNP
Cetuximab and Vemurafenib Plus FOLFIRI for BRAF V600E Mutated Advanced Colorectal Cancer (IMPROVEMENT): A Single-arm Study. --- V600E ---
Cetuximab and Vemurafenib Plus FOLFIRI for BRAF V600E Mutated Advanced Colorectal Cancer (IMPROVEMENT) This clinical trial aims to evaluate the efficacy, safety of FOLFIRI with vemurafenib and cetuximab in Advanced Colorectal Cancer Patients with BRAF V600E mutation. --- V600E ---
Cetuximab and Vemurafenib Plus FOLFIRI for BRAF V600E Mutated Advanced Colorectal Cancer (IMPROVEMENT) This clinical trial aims to evaluate the efficacy, safety of FOLFIRI with vemurafenib and cetuximab in Advanced Colorectal Cancer Patients with BRAF V600E mutation. --- V600E --- --- V600E ---
Inclusion Criteria: - Patients should be histologically diagnosed with advanced colorectal adenocarcinoma or postoperative recurrence; - Patients with BRAF V600E mutation and extended RAS wild type; - Patients have measurable lesions; - Patients are not available for targeted therapy or patients refuse to receive targeted therapy; - Age should be 18-25 years; - Performance status should be 0-2; Exclusion Criteria: - Patients with RAS mutation type; - Patients with brain metastases; - Patients could not tolerate chemotherapy; - Patients have secondary primary tumor Inclusion Criteria: - Patients should be histologically diagnosed with advanced colorectal adenocarcinoma or postoperative recurrence; - Patients with BRAF V600E mutation and extended RAS wild type; - Patients have measurable lesions; - Patients are not available for targeted therapy or patients refuse to receive targeted therapy; - Age should be 18-25 years; - Performance status should be 0-2; Exclusion Criteria: - Patients with RAS mutation type; - Patients with brain metastases; - Patients could not tolerate chemotherapy; - Patients have secondary primary tumor Colorectal Cancer Colorectal Neoplasms null --- V600E ---
Inclusion Criteria: - Patients should be histologically diagnosed with advanced colorectal adenocarcinoma or postoperative recurrence; - Patients with BRAF V600E mutation and extended RAS wild type; - Patients have measurable lesions; - Patients are not available for targeted therapy or patients refuse to receive targeted therapy; - Age should be 18-25 years; - Performance status should be 0-2; Exclusion Criteria: - Patients with RAS mutation type; - Patients with brain metastases; - Patients could not tolerate chemotherapy; - Patients have secondary primary tumor Inclusion Criteria: - Patients should be histologically diagnosed with advanced colorectal adenocarcinoma or postoperative recurrence; - Patients with BRAF V600E mutation and extended RAS wild type; - Patients have measurable lesions; - Patients are not available for targeted therapy or patients refuse to receive targeted therapy; - Age should be 18-25 years; - Performance status should be 0-2; Exclusion Criteria: - Patients with RAS mutation type; - Patients with brain metastases; - Patients could not tolerate chemotherapy; - Patients have secondary primary tumor Colorectal Cancer Colorectal Neoplasms null --- V600E --- --- V600E ---